Subscribe

Onward Medical N.V. (ONWD.BR)

EUR2.49 +0.01 (+0.40%)
NL BRU Healthcare Biotechnology
Address High Tech Campus 32 5656 AE
Eindhoven, NL
CEO David L. Marver
Website onwd.com
IPO 2021-10-21
ISIN NL0015000HT4

Explore sections of this company profile

Description

Onward Medical N.V. is a medical technology company dedicated to developing innovative therapies for spinal cord injuries, operating both within the Netherlands and internationally. Among its primary offerings is ARCEX, a non-invasive, external platform. This system incorporates a wearable stimulator and a wireless programmer, designed to restore or significantly enhance hand and arm motor function for individuals living with spinal cord injuries. Complementing this is ARCIM, an implantable platform. ARCIM features an implantable pulse generator and a lead positioned near the spinal cord, empowering individuals with chronic paralysis to regain the ability to stand and walk, often with minimal or no external assistance. The company is also currently advancing the Up-LIFT Trial, a clinical study evaluating the safety and efficacy of ARCEX Therapy in restoring strength and mobility in the upper extremities of those affected by spinal cord injury. Established in 2014, Onward Medical N.V. maintains its headquarters in Eindhoven, Netherlands.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
EUR2.49 +0.01 (+0.40%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
186.7K
Beta
0.85
Float Shares
43.65M
Free Float %
93.5%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-3.47% +3.15% -10.16% -32.07% -34.78% -37.97% -36.12% -42.58% -78.14% -78.14% -78.14%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
2.49
Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 5 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-2.89
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Biotechnology: +1.6%
    +4,809.1% ★ Q4'25: +755.3% (vs Q4'23)
  • ✗
    EPS growth Biotechnology: +29.7%
    -17.5% Q4'25: +16.1% (vs Q4'23)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -1,103.8% Q4'25: -788.5% (vs Q4'23)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -1,038.6% Q4'25: -743.2% (vs Q4'23)
  • ✗
    ROIC Biotechnology: -16.1%
    -4,507.5% Q4'25: -8,857.4% (vs Q4'23)
  • ✗
    Share dilution Biotechnology: -3.4%
    +0.0% ★ Q4'25: +47.9% (vs Q4'23)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -0.36× Q4'25: -0.19× (vs Q4'23)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.85) × ERP
WACC = 90% × Ke + 10% × Kd (16.2%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 2.49
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
4 Rev. Ana.
3 EPS Ana. 		Dec 2027
5 Rev. Ana.
4 EPS Ana. 		Dec 2028
1 Rev. Ana.
3 EPS Ana. 		Dec 2029
2 Rev. Ana.
2 EPS Ana.
Revenue
1.40M
est: 1.20M (+16.6%)
2.15M
est: 400.0K (+437.0%)
532.0K
est: 1.80M (-70.4%)
77.0K
est: 1.68M (-95.4%)
3.78M
est: 5.00M (-24.5%)
13.37M
12.37M – 14.16M
+167.1% YoY
34.03M
21.04M – 49.76M
+154.6% YoY
57.60M
40.24M – 78.15M
+69.2% YoY
155.58M
108.68M – 211.09M
+170.1% YoY
EBITDA
-28.30M
est: -1.20M (-2,258.5%)
-31.26M
est: -400.0K (-7,713.8%)
-35.23M
est: -1.80M (-1,857.4%)
-32.87M
est: -1.68M (-1,862.3%)
-37.81M
est: -5.00M (-655.6%)
-13.37M
-14.16M – -12.37M
-167.1% YoY
-34.03M
-49.76M – -21.04M
-154.6% YoY
-57.60M
-78.15M – -40.24M
-69.2% YoY
-155.58M
-211.09M – -108.68M
-170.1% YoY
EBIT
-28.63M
est: -1.20M (-2,285.9%)
-32.03M
est: -400.0K (-7,907.0%)
-35.46M
est: -1.80M (-1,870.2%)
-33.77M
est: -1.68M (-1,915.9%)
-39.26M
est: -5.00M (-684.5%)
-13.37M
-14.16M – -12.37M
-167.1% YoY
-34.03M
-49.76M – -21.04M
-154.6% YoY
-57.60M
-78.15M – -40.24M
-69.2% YoY
-155.58M
-211.09M – -108.68M
-170.1% YoY
Net Income
-34.31M
est: -24.99M (-37.3%)
-32.77M
est: -46.86M (+30.1%)
-36.18M
est: -49.54M (+27.0%)
-35.73M
est: -47.02M (+24.0%)
-41.79M
est: -35.84M (-16.6%)
-38.46M
-40.81M – -36.12M
-7.3% YoY
-28.12M
-44.41M – -10.13M
+26.9% YoY
-20.98M
-30.71M – -12.76M
+25.4% YoY
14.76M
8.97M – 21.60M
+170.3% YoY
SGA
7.76M
est: 84.05M (-90.8%)
20.30M
est: 28.02M (-27.5%)
15.73M
est: 126.08M (-87.5%)
23.24M
est: 116.90M (-80.1%)
9.79M
est: 349.29M (-97.2%)
932.91M
863.29M – 988.60M
+167.1% YoY
2.38B
1.47B – 3.47B
+154.6% YoY
4.02B
2.81B – 5.45B
+69.2% YoY
10.86B
7.59B – 14.73B
+170.1% YoY
EPS
-1.14
est: -0.56 (-103.6%)
-1.09
est: -1.05 (-3.8%)
-1.20
est: -1.11 (-8.1%)
-0.80
est: -1.05 (+24.1%)
-0.94
est: -0.80 (-17.1%)
-0.86
-0.91 – -0.81
-7.3% YoY
-0.63
-0.99 – -0.23
+26.9% YoY
-0.47
-0.69 – -0.29
+25.4% YoY
0.33
0.20 – 0.48
+170.3% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-11 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-08 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-07 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-06 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-05 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-05-04 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-04-30 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-04-29 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-04-28 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-04-27 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-04-24 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-04-23 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-17 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-16 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-68.66M
OE per share TTM
-1.64
Owner's Yield
-53.22%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
108.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 3 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Dimensional - International Small Cap ETF DFIS 0.00% 80.1K 0.39%
2 Dimensional - International Core Equity 2 ETF DFIC 0.00% 25.8K 0.22%
3 Dimensional - International Core Equity Market ETF DFAI 0.00% — 0.18%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-3.8K
Shares Outstanding
46.67M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
David L. Marver Chief Executive Officer & Executive Director 1M male
Ali Kiboro Chief Financial Officer — male
Gregoire Courtine Co-Founder & Senior Advisor — male
Julie Crom Director of People & Culture — female
Lorenzo Fanti Vice President of Legal — male
Robert W. Odell Vice President of Operations — male
Sean Sciara Chief Commercial Officer — male
Sebastien Cros Vice President of Communications — male
Alexandre Casteau Head of Strategy & Corporate Development — male
Shari O'Quinn Chief Clinical, Regulatory & Quality Officer — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology